Clinical trial
A Study of a New Assay to Detect Anti-drug Antibodies to Alemtuzumab and Their Potential Impact in Multiple Sclerosis
NCT06310343 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of a New Assay to Detect Anti-drug Antibodies to Alemtuzumab and Their Potential Impact in Multiple Sclerosis
- Lead sponsor
- Queen Mary University of London
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 12, 2022
- Completion date
- October 17, 2025
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.